Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide
2004 (English)In: Neuroendocrinology, ISSN 0028-3835, E-ISSN 1423-0194, Vol. 80, no 4, 244-251 p.Article in journal (Other academic) Published
This 6-month, open, non-controlled, multicenter, dose-titration study evaluated the efficacy and safety of 28-day prolonged-release (PR) lanreotide in the treatment of carcinoid syndrome. Eligible patients had a carcinoid tumor with > or =3 stools/day and/or > or =1 moderate/severe flushing episodes/day. Six treatments of 28-day PR lanreotide were administered by deep subcutaneous injection. The dose for the first two injections was 90 mg. Subsequent doses could be titrated (60, 90, 120 mg) according to symptom response. Seventy-one patients were treated. Flushing decreased from a mean of 3.0 at baseline to 2.3 on day 1, and 2.0 on day 2, with a daily mean of 2.1 for the first week post-treatment (p < 0.05). Diarrhea decreased from a mean of 5.0 at baseline to 4.3 on day 1 (p < 0.05), and 4.5 on day 2, with a daily mean of 4.4 for the first week post-treatment (p < 0.001). Symptom frequency decreased further after the second and third injections, and reached a plateau after the fourth injection. By month 6, flushing and diarrhea had significantly decreased from baseline by a mean of 1.3 and 1.1 episodes/day, respectively (both p < or = 0.001); 65% of patients with flushing as the target symptom and 18% of diarrhea-target patients achieved > or =50% reduction from baseline. Median urinary 5-hydroxyindoleacetic acid and chromogranin A levels decreased by 24 and 38%, respectively. Treatment was well tolerated. 28-day PR lanreotide was effective in reducing the symptoms and biochemical markers associated with carcinoid syndrome.
Place, publisher, year, edition, pages
2004. Vol. 80, no 4, 244-251 p.
Adult, Aged, Aged; 80 and over, Chromogranins/blood, Comparative Study, Delayed-Action Preparations/*therapeutic use, Dose-Response Relationship; Drug, Drug Administration Schedule, Drug Evaluation/methods, Female, Flushing/drug therapy/physiopathology, Humans, Hydroxyindoleacetic Acid/urine, Male, Malignant Carcinoid Syndrome/complications/*drug therapy/metabolism, Middle Aged, Peptides; Cyclic/blood/*therapeutic use, Quality of Life, Research Support; Non-U.S. Gov't, Somatostatin/*analogs & derivatives/blood/*therapeutic use, Time Factors, Treatment Outcome, Vipoma/drug therapy/physiopathology
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-70003DOI: 10.1159/000082875PubMedID: 15627802OAI: oai:DiVA.org:uu-70003DiVA: diva2:97914